Core Viewpoint - Sanofi's Board of Directors is proposing the appointment of Christel Heydemann as an independent director at the upcoming Annual General Meeting on April 29, 2026, alongside the renewal of existing mandates for Christophe Babule and Jean-Paul Kress [1][4]. Group 1: Board Composition Changes - Christel Heydemann, currently the CEO of the Orange Group since April 2022, has a diverse background in management, having held various positions at Alcatel and Schneider Electric, which will enhance the Board's expertise [3][4]. - Patrick Kron, an independent director and Chairman of the Nomination, Governance and CSR Committee, will step down at the end of his term during the upcoming Annual General Meeting, after 12 years of service [2][4]. - The Board will maintain a total of 16 members post-appointments, including two employee representatives, achieving gender parity with 57% of women (excluding employee representatives) [4]. Group 2: Governance and Strategic Direction - The proposed appointment of Christel Heydemann is aimed at strengthening the diversity of expertise within the Board, which is crucial for Sanofi's strategic vision and industrial transformation [4]. - The composition of the Board's specialized committees will be reviewed following the Annual General Meeting scheduled for April 29, 2026 [5]. Group 3: Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines, addressing urgent healthcare and societal challenges [6].

Core Viewpoint - Sanofi's Board of Directors is proposing the appointment of Christel Heydemann as an independent director at the upcoming Annual General Meeting on April 29, 2026, alongside the renewal of existing mandates for Christophe Babule and Jean-Paul Kress [1][4]. Group 1: Board Composition Changes - Christel Heydemann, currently the CEO of the Orange Group since April 2022, has a diverse background in management, having held various positions at Alcatel and Schneider Electric, which will enhance the Board's expertise [3][4]. - Patrick Kron, an independent director and Chairman of the Nomination, Governance and CSR Committee, will step down at the end of his term during the upcoming Annual General Meeting, after 12 years of service [2][4]. - The Board will maintain a total of 16 members post-appointments, including two employee representatives, achieving gender parity with 57% of women (excluding employee representatives) [4]. Group 2: Strategic Focus - The proposed appointment of Christel Heydemann is aimed at strengthening the diversity of expertise within the Board, which is crucial for supporting Sanofi's next phase of development [4]. - Sanofi is committed to addressing urgent healthcare, environmental, and societal challenges through its innovative pipeline, which is driven by research and development [6].